What evidence challenges the stability of IBD subtype classification over 10 years, and are there conflicting reported reclassification rates between CD and UC

What is known

- A European cohort's 10-year follow-up confirmed a cumulative reclassification rate of 32%, and a Scottish pediatric cohort with up to 20 years showed reclassification in the majority. ^1,2 - In a large cohort of 44,302 patients, 18% changed diagnosis over median 3.8 years; 67% of IBD-U visits were followed by another IBD-U diagnosis, and among all changes 39% went UC to CD and 33% CD to UC. ³ - A pediatric meta-analysis pooled 50% overall reclassification, with 30% to UC and 20% to CD, and after excluding one outlier study found UC (32.7%) significantly exceeded CD (17%). ⁴ - Conflicting series report most reclassification to CD (70% in one study, 83% to CD in an Israeli cohort with 54% overall reclassification), contrasting with UC-predominant findings elsewhere. ^2,5 - A Chinese multicentre study reclassified 24% as UC and 22% as CD after nearly 7 years, with haemorrhage predicting CD and hypoalbuminaemia predicting UC. ¹

What is unknown / caveats

- Reclassification skews toward CD in some pediatric series (e.g., 70% and 83% to CD) but toward UC in the pooled meta-analysis (30% UC vs 20% CD) - Low reclassification rates argue IBDU is a true intermediate phenotype, while rates as high as 80% argue it is only a provisional diagnosis - Much of the evidence is pediatric IBDU-specific rather than general adult CD-vs-UC stability - High statistical heterogeneity (I2 up to 83%) and varied follow-up durations across studies - Part of reclassification attributed to incomplete initial diagnostic workup rather than true disease evolution - Regional differences in diagnostic criteria applied to reach an IBD-U label - Whether reclassification reflects true disease evolution or original misdiagnosis from incomplete workup remains unresolved in the excerpts.

## References

1. Latorre MA, Rennie M, Rosiou K, Lenti MV, Selinger CP. Long-term classification stability and treatment patterns of inflammatory bowel disease unclassified: a longitudinal observational study. BMJ Open Gastroenterol. 2026;13(1). PMID: 42276737.

2. Wands DIF, Gianolio L, Cameron F, Hansen R, Russell RK, Wilson DC. Pediatric Inflammatory Bowel Disease Type Unclassified: A Nationwide Cohort Study in Scotland With up to 20 Years Follow-up Shows Reclassification in the Majority and Mild Course in Those Whose Diagnosis Is Unchanged. Inflamm Bowel Dis. 2025;31(2):313-320. PMID: 39321100.

3. Everhov ÅH, Sachs MC, Malmborg P, Nordenvall C, Myrelid P, Khalili H, Elmberg M, Ekbom A, Askling J, Jakobsson G, Halfvarson J, Ludvigsson JF, Olén O. Changes in inflammatory bowel disease subtype during follow-up and over time in 44,302 patients. Scand J Gastroenterol. 2019;54(1):55-63. PMID: 30700170.

4. Bolia R, Goel AD. SYSTEMATIC REVIEW AND META - ANALYSIS OF THE FREQUENCY AND RE-CLASSIFICATION TRENDS OF PEDIATRIC INFLAMMATORY BOWEL DISEASE - UNCLASSIFIED. Arq Gastroenterol. 2022;59(4):531-539. PMID: 36515348.

5. Thurgate LE, Lemberg DA, Day AS, Leach ST. An Overview of Inflammatory Bowel Disease Unclassified in Children. Inflamm Intest Dis. 2019;4(3):97-103. PMID: 31559261.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

---

_Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct._